SiR-The presence of certain types of human papillomaviruses (HPV) are one of the major
risk factors in the development of malignancies of the uterine cervix. However, factors other …

(A) Risk of infection when HPV vaccination is given only to girls aged 12–16 years when
resuming vaccination encouragement.(B) Risk of infection when HPV vaccination is given to …

Background Although the peak incidence of human papillomavirus (HPV) infection occurs in
most populations within 5–10 years of first sexual experience, all women remain at risk for …

Since the introduction of the human papillomavirus (HPV) vaccine in 2006, the evidence
regarding its efficacy and safety has continued to highlight its importance in cancer …

Heidi Larson and colleagues in their Comment, 1 and Mark Feinberg of Merck in his
response, 2 call for more effective ways to engage with public advocates who question new …

Background Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will
require a high level of sustained protection against infection and precancerous lesions. Our …

1 Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al, for the Costa Rica Vaccine Trial
and the PATRICIA study groups. Efficacy of fewer than three doses of an HPV-16/18 AS04 …

In The Lancet Oncology, Nicole Polman and colleagues1 report the results of a randomised
trial, nested in the Dutch cervical screening programme, in which clinical performance of …

In the Lancet Infectious Diseases, Eric Chow and colleagues1 present evidence of
remarkable population effectiveness against human papillomavirus (HPV), with virtual …

Objective Nine-valent human papillomavirus (9vHPV) vaccine efficacy against disease and
cervical surgeries related to all nine vaccine components was assessed compared with a …